坚持他汀中国剂量主旋律
发布时间：2018-10-23 08:14
【摘要】：本文在对2016年中国成人血脂指南的核心要点述评基础上,针对欧洲血脂指南低密度脂蛋白胆固醇(LDL-C)目标值中的问题,结合中国临床实际和循证研究证据,强调中、小剂量他汀是我国大多数血脂异常患者降脂达标策略,本文明确指出对推荐使用中、小他汀类药物来防治中国的动脉粥样硬化性心血管疾病(ASCVD)患者无可争议。我们没有理由用大剂量他汀治疗中国的患者,更不应该对急性冠状动脉综合征(ACS)和经皮冠状动脉介入术(PCI)的患者突击使用阿托伐他汀80mg的序贯疗法。呼吁广大的临床医生要在落实推广中国血脂指南的工作中,用最美的音符共同奏响降脂达标坚持他汀中国剂量的主旋律。
[Abstract]:On the basis of a review of the key points of the 2016 Chinese Adult Lipid guidelines, this paper focuses on the problems in the target values of low density lipoprotein cholesterol (LDL-C) in the European guidelines for lipids, combined with the evidence of clinical practice and evidence-based research in China, emphasizing that, Low dose statins is the strategy of lowering lipid standard in most patients with dyslipidemia in China. This article clearly points out that it is undisputed for the recommended use of small statins to prevent and treat (ASCVD) patients with atherosclerotic cardiovascular disease in China. There is no reason to treat Chinese patients with high doses of statins, nor should we surprise patients with acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) with Atto vastatin 80mg sequential therapy. In the process of popularizing the guidelines of blood lipid in China, the most beautiful notes should be used to play the main melody of statin dosage in China.
【作者单位】： 长春中医药大学附属医院;北京大学人民医院;
【分类号】：R972.6
本文编号：2288641
[Abstract]:On the basis of a review of the key points of the 2016 Chinese Adult Lipid guidelines, this paper focuses on the problems in the target values of low density lipoprotein cholesterol (LDL-C) in the European guidelines for lipids, combined with the evidence of clinical practice and evidence-based research in China, emphasizing that, Low dose statins is the strategy of lowering lipid standard in most patients with dyslipidemia in China. This article clearly points out that it is undisputed for the recommended use of small statins to prevent and treat (ASCVD) patients with atherosclerotic cardiovascular disease in China. There is no reason to treat Chinese patients with high doses of statins, nor should we surprise patients with acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) with Atto vastatin 80mg sequential therapy. In the process of popularizing the guidelines of blood lipid in China, the most beautiful notes should be used to play the main melody of statin dosage in China.
【作者单位】： 长春中医药大学附属医院;北京大学人民医院;
【分类号】：R972.6
【相似文献】
相关期刊论文 前10条
1 ;新的治疗血脂异常药物[J];中华高血压杂志;2007年06期
2 陆宗良,杜保民;血脂异常的治疗[J];中国新药杂志;1999年06期
3 靳和平;;引起血脂异常的8种药[J];医药保健杂志;2006年21期
4 黄佳;血脂异常的药物治疗新进展[J];广西医学;1997年06期
5 刘川;调血脂和抗动脉粥样硬化药物的应用现状和进展趋势[J];中国新药杂志;2005年11期
6 ;血脂异常药市场前景广阔[J];中国信息界(e医疗);2013年11期
7 张春,姜立清,孙永安,王言理,贺玉钦;不同剂量藻酸双酯钠对血脂异常的调节作用[J];中国临床药学杂志;2001年04期
8 王义勇;贾绍斌;陈大鹏;刘静;张政军;候建军;;阿托伐他汀钙对血脂异常大鼠主动脉组织bcl-2基因甲基化的影响[J];临床心血管病杂志;2012年09期
9 刘晓婷;阿丽塔;张玢;孙涛涛;许培扬;唐小利;;胆固醇酯转移蛋白抑制剂开发[J];世界临床药物;2013年07期
10 黄世杰;;福沙那韦可致心肌梗死和血脂异常[J];国际药学研究杂志;2010年05期
相关重要报纸文章 前1条
1 北京大学人民医院教授 徐成斌;他汀不能解决所有血脂问题[N];健康报;2010年
，本文编号：2288641
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2288641.html
最近更新
教材专著
